Yitian LuoManaging Director at YunFeng Capital
Mr. Luo Yitian is the founder of Yunfeng Healthcare Practice, and currently responsible for the investment and management in the field of healthcare in Yunfeng Capital. Prior to joining Yunfeng, he worked for Decheng Capital and Bay City Capital, a biomedical specialty fund, and focused on investment opportunities in biotechnology and pharmaceutical sector in China, and the United States. Previously, he was the co-founder of Meritco-Services, the fifth largest management consulting firm in China currently. Prior to that, Yitian worked for McKinsey & Company as a pharmaceutical specialist. Mr. Luo Yitian has extensive investment and management experience in the healthcare field. His investment expertise includes early and growth stage private equity investment, cross-border M&A and privatization, and serves as director and executive director of various companies.
Parts of Mr.Yitian Luo’s investments and exits include: Pre-IPO investment of CBPO (NASDAQ:CBPO), Privatization of 3SBIO (HK 01530) and Wuxi Pharma ( A: 603259), minority investment of Wuxi NextCode, and Cstone pharma (HK 2616), cross-border acquisition of Esaote Medical (Italy based), asset acquisition of LivaNova global CRM business (Sorin), buyout investment of Relia Biotech (sold to a China leading IVD player); Spin-off investment of Livizon (A:000513, H 01513) biopharma business